Purpureocillium lilacinum as unusual cause of pulmonary infection in immunocompromised hosts.


Journal

Journal of infection in developing countries
ISSN: 1972-2680
Titre abrégé: J Infect Dev Ctries
Pays: Italy
ID NLM: 101305410

Informations de publication

Date de publication:
30 04 2020
Historique:
received: 21 11 2019
accepted: 19 02 2020
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 20 7 2021
Statut: epublish

Résumé

Purpureocillium lilacinum (P. lilacinum) is an emergent pathogenic mold that presents more commonly as an ocular infection, cutaneous and/or subcutaneous infections in patients that are usually immunocompromised. A pulmonary presentation is rare, the clinical presentation is fever and cough with radiographic presentation as pleural effusion, single-lung consolidation, and cavitary pulmonary disease. We present a case of a patient with hematologic malignancy with febrile neutropenia; after receiving chemotherapy, the patient developed a pulmonary infection with multiple bilateral consolidations shown in the thoracic computed tomography scan. Fever persisted in spite of the use of wide-spectrum antibiotics and amphotericin. Bronchoalveolar lavage was performed and the samples were cultured, isolating in the Sabouraud Dextrous Agar a filamentous fungi growth with purple colonies that were identified morphologically as P. lilacinum and later it was confirmed by molecular methods. Once the infectious agent was identified, we continued amphotericin and oral voriconazole was added to the treatment with complete resolution of the infection. The report aims to create awareness of this emerging infectious disease, as there is little information concerning the treatment and the prognosis of patients infected by P. lilacinum with a pulmonary presentation.

Identifiants

pubmed: 32379722
doi: 10.3855/jidc.12235
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

415-419

Informations de copyright

Copyright (c) 2020 Manuel A Salazar-Gonzalez, Jorge R Violante-Cumpa, Christian G Alfaro-Rivera, Hiram Villanueva-Lozano, Rogelio de Jesus Trevino-Rangel, Gloria M Gonzalez.

Déclaration de conflit d'intérêts

No Conflict of Interest is declared

Auteurs

Manuel A Salazar-González (MA)

Department of Internal Medicine. Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León. Monterrey, México. dr.msalazar13@gmail.com.

Jorge R Violante-Cumpa (JR)

Department of Internal Medicine. Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León. Monterrey, México. jorge_violante@hotmail.com.

Christian G Alfaro-Rivera (CG)

Department of Infectious Diseases. Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León. Monterrey, Nuevo León, México. dr.chalfaro@gmail.com.

Hiram Villanueva-Lozano (H)

Department of Microbiology. Facultad de Medicina, Universidad Autónoma de Nuevo León. Monterrey, Nuevo León, México. dr.villanueval@hotmail.com.

Rogelio de Jesús Treviño-Rangel (RJ)

Department of Microbiology. Facultad de Medicina, Universidad Autónoma de Nuevo León. Monterrey, Nuevo León, México. rogdejesus@hotmail.com.

Gloria M González (GM)

Department of Microbiology. Facultad de Medicina, Universidad Autónoma de Nuevo León. Monterrey, Nuevo León, México. gmglez@yahoo.com.mx.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH